<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347567">
  <stage>Registered</stage>
  <submitdate>6/10/2011</submitdate>
  <approvaldate>7/10/2011</approvaldate>
  <actrnumber>ACTRN12611001051932</actrnumber>
  <trial_identification>
    <studytitle>Mifepristone for early termination of pregnancy.</studytitle>
    <scientifictitle>Termination of early pregnancy using mifepristone 200mg followed by buccal administration of misoprostol 800mcg  retrospective review of efficacy and safety  Australian Authorised Prescriber Program.</scientifictitle>
    <utrn>NIL</utrn>
    <trialacronym>NA</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Termination of first trimester pregnancy.</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Abortion</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Mifepristone 200mg tablet followed 36-48 hours later by misoprostol 800mcg tablets by buccal administration. Observation for adverse events for up to 21 days post treatment.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of procedure failure as measured by pregnancy test and ultrasound.</outcome>
      <timepoint>14 to 21 days post treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>incidence of adverse events - reported to clinic following treatment.  Serious adverse events associated with the procedure include hemorrhage, retained products of conception and very rarely, infection.</outcome>
      <timepoint>Adverse events are monitored from day of treatment to follow up which is most often up to 14 to 21 days post treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient preferences at follow up - completion of a patient questionnaire regarding patients experience of pain, bleeding and overall satisfaction with the procedure.</outcome>
      <timepoint>A follow up appointment occurs in the time period of 14 to 21 days post dosing and at that visit a patient questionnaire is completed.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Confirmed pregnancy up to 9 weeks gestation.
Informed consent.
No contraindications.
Must meet legal requirements for termination of pregnancy in the state where the service is provided.</inclusivecriteria>
    <inclusiveminage>14</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>More than 9 weeks since the last menstrual period (confirmed by ultrasound).
Known or suspected ectopic pregnancy.
Concomitant administration of anticoagulants or corticosteroids.
Adrenal failure, inherited porphyria or a haemorrhagic disorder.
Allergy to mifepristone or misoprostol.
Intrauterine device insitu
Pelvic infection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>9/08/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>13000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Marie Stopes International Australia</primarysponsorname>
    <primarysponsoraddress>GPO Box 1635, Melbourne, Victoria, Australia 3001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Marie Stopes International Australia</fundingname>
      <fundingaddress>GPO Box 1635, Melbourne, Victoria, Australia 3001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A retrospective review of the safety and efficacy of the use of mifepristone 200mg with misoprostol 800mcg buccally for termination of pregnancy less than 9 weeks gestation.  Summary of the findings from an Authorised Prescriber program in Australia.</summary>
    <trialwebsite>NA</trialwebsite>
    <publication>NA</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland Clinical Trials Network</ethicname>
      <ethicaddress>PO Box 2366, Toowong DC, 4066, Qld, Australia</ethicaddress>
      <ethicapprovaldate>30/05/2009</ethicapprovaldate>
      <hrec>EC00427</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Business Development Director</name>
      <address>Marie Stopes International Australia
PO Box 1635
Melbourne 3001
Victoria, Australia</address>
      <phone>+613 9658 7533</phone>
      <fax />
      <email>info@mariestopes.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Business Development Director</name>
      <address>Marie Stopes International Australia
PO Box 1635
Melbourne 3001
Victoria 
Australia</address>
      <phone>+613 9658 7533</phone>
      <fax />
      <email>info@mariestopes.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Business Development Director</name>
      <address>Marie Stopes International Australia
PO Box 1635
Melbourne 3001</address>
      <phone>+613 9658 7533</phone>
      <fax />
      <email>info@mariestopes.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>